31 January 2019: Diabetic
Nephropathy Market a progressive kidney disease triggered by
damage to the capillaries in the kidney glomeruli. The causes of diabetic
nephropathy include factors such as high blood sugar, high cholesterol,
excessive smoking, and advanced glycation end product formation. In case of the
symptoms, there are no symptoms in the early stage. Therefore, it is important
to undergo regular urine tests to discover if there is kidney damage.
Generally, the symptoms appear after the kidney starts damaging. Some of the
late symptoms include nausea, headache, lack of appetite, itchy skin, severe
tiredness, leg swelling, etc.
The diagnosis is carried out by a test which is based on the
measurement of high levels of a protein namely albumin in the urine. The
factors that propel the growth of the global Diabetic Nephropathy market size
include increasing incidence of diabetes, and growing R&D activities and
investments in drug discovery. In addition, expanding awareness regarding
diabetes diseases treatment and also an upsurge in use of combination therapy
is projected to drive the growth of the global Diabetic Nephropathy market
size. On the other hand, there are also
factors that hamper the growth of the market size such as growing number of
patent expirations and strict rules & regulations and time-consuming
product authorization procedures for drugs. The global Diabetic Nephropathy
market size is classified on the basis of treatment type and geography.
Request Sample Copy
of This Market Research @ https://www.millioninsights.com/industry-reports/diabetic-nephropathy-market/request-sample
On the basis of treatment type, the global Diabetic
Nephropathy market size is classified as Angiotensin-Converting Enzyme
Inhibitors, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers,
Calcium Channel Blockers, Connective Tissue Growth Factor Inhibitors,
Diuretics, Endothelin-A Receptor Antagonist, G Protein-Coupled Receptors, Renin
Inhibitors and Monocyte Chemoattractant Proteins Inhibitor. On the basis of
geography, the global Diabetic Nephropathy market size is classified as North
America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding
Japan, Japan and Middle East and Africa.
The North American region comprises the U.S., and Canada. Latin America
region comprises Mexico, Brazil, and Rest of Latin America. The Western
European region comprises Germany, Italy, England, Spain, France, Nordic
countries, BENELUX, and Rest of Western Europe. The Eastern European region
comprises Russia, Poland, and Rest of Eastern Europe. Asia Pacific Excluding
Japan comprises China, India, ASEAN, Australia & New Zealand, and Rest of
APEJ. The Middle East and Africa comprises GCC countries, S. Africa, N. Africa,
and Rest of MEA.
In case of geographical region, North America is projected
to dominate a major share of the global Diabetic Nephropathy market. The
factors that attribute to this major share are owed to increased combination
drugs usage and also rising awareness regarding several kidney diseases. The
North American market is followed by Europe; Europe is the second major market
of the global Diabetic Nephropathy market owing to growing incidence of
diabetes and rise in healthcare expenditure for diabetes treatment in the
region. On the other hand, Asia Pacific Excluding Japan market is projected to grow
at rapidly during the forecast period due to presence of large patient pool,
increase in disposal for healthcare treatment and increased awareness regarding
novel diabetic drugs in the market.
Some of the key players that fuel the growth of the global
Diabetic Nephropathy market include Merck & Co. Inc., Mitsubishi Tanabe
Pharma Corp., Novartis AG and Sanofi S.A.
The prominent other players include AbbVie Inc., Ampio Pharmaceuticals
Inc., OncoImmune Inc., Pfizer Inc., IMMD Inc., Mesoblast Ltd., NephroGenex
Inc., Questcor Pharmaceuticals Inc., Reata Pharmaceuticals Inc., GenKyoTex
S.A., Astellas Pharma Inc., Bayer AG, ChemoCentryx Inc., Eli Lilly and Co.,
Glycadia Pharmaceuticals Inc., Novo Nordisk A/S, NOXXON Pharma AG, and
PhytoHealth Corp.
Browse Full Research Report
@ https://www.millioninsights.com/industry-reports/diabetic-nephropathy-market
Get in touch
At Million Insights, we work
with the aim to reach the highest levels of customer satisfaction. Our
representatives strive to understand diverse client requirements and cater to
the same with the most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist,
USA
Email: ryan@millioninsights.com
Million Insights
Office No. 302, 3rd Floor,
Manikchand Galleria,
Model Colony, Shivaji Nagar,
Pune, MH, 411016 India
tel: 91-20-65300184
Email: sales@millioninsights.com
Visit Our Blog: www.millioninsights.blogspot.com
No comments:
Post a Comment